

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Jinhai Medical Technology Limited**

**今海醫療科技股份有限公司**

*(Incorporated in the Cayman Islands with members' limited liability)*

**(Stock Code: 2225)**

### **PROFIT WARNING**

This announcement is made by Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 (the “**1H2024**”) and other information currently available to the Board, the Group is expected to record a loss after taxation of approximately S\$6.0 million as compared to a profit after taxation for the six month ended 30 June 2023 (“**1H2023**”) of approximately S\$590,000. Based on the unaudited consolidated management accounts of the Group for 1H2024, the Board considered that the business of the Group showed a positive development during 1H2024. The Group recorded revenue of approximately S\$25.9 million and gross profit of approximately S\$7.4 million for 1H2024, which represented a positive improvement as compared to revenue of approximately S\$12.0 million and gross profit of approximately S\$5.0 million for 1H2023. The turnaround from net profit position for 1H2023 to the net loss position for 1H2024 was principally attributable to, amongst others, the incurrence of expenses on equity-settled share-based payments in the amount of approximately S\$6.5 million, as a result of grant of share options to certain employees of the Group during 1H2024 (1H2023: nil).

As the Company is still in the process of finalising the interim results of the Group for 1H2024, the information contained in this announcement is only based on the preliminary assessment by the Board by reference to the unaudited consolidated management accounts of the Group for the 1H2024, which have not been audited or reviewed by the Company’s independent auditor or the audit committee of the Board, respectively and is subject to adjustment. The interim unaudited consolidated financial results of the Group for 1H2024 are expected to be published in August 2024.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Jinhai Medical Technology Limited**  
**Chen Guobao**  
*Chairman of the Board and executive Director*

Hong Kong, 21 August 2024

*As at the date of this announcement, the Board comprises eight Directors, of which four are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping and Mr. Dai Yong; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.*